Tivic Health targets FDA approval for Entolimod within 18 months, highlights transformation into biopharma

Mar. 21, 2025 6:32 PM ETTivic Health Systems, Inc. (TIVC) StockAI-Generated Earnings Calls Insights
(6min)

Earnings Call Insights: Tivic Health Systems (TIVC) Q4 2024

Management View

  • CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, which aims to treat acute radiation syndrome (ARS). Over $140 million has been
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

More Trending News

About TIVC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TIVC--
Tivic Health Systems, Inc.